Sino Biopharmaceutical’s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma – 72.4% ORR and Unreached Median PFS in Rare Cancer Indication

The National Medical Products Administration (NMPA) has granted approval to Chia Tai Tianqing Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Sino Biopharmaceutical Limited (HKG: 1177), for the combination of benmelstobart (anti-PD-L1 monoclonal antibody) and anlotinib (oral multi-target kinase inhibitor) in the treatment of advanced or unresectable alveolar soft part sarcoma (ASPS). The approval, supported by the TQB2450-Ib-02 study showing a 72.41% objective response rate (ORR) and unreached median progression-free survival (PFS) after 24.9 months of follow-up, follows Breakthrough Therapy Designation and Priority Review status, marking the combo’s fourth approved indication in China.

Regulatory Milestone

Clinical Trial Results – TQB2450-Ib-02 Study

Drug Profile & Mechanism

• Benmelstobart: Anti-programmed death-ligand 1 (PD-L1) monoclonal antibody that enhances anti-tumor immune response
• Anlotinib: Oral multi-target tyrosine kinase inhibitor with anti-angiogenic and direct anti-tumor effects
• Combination Rationale: Dual mechanism targeting both tumor microenvironment (immune checkpoint inhibition) and tumor vasculature/signaling pathways (kinase inhibition)
• ASPS Context: Rare soft tissue sarcoma affecting primarily young adults, with limited treatment options and poor prognosis with conventional therapies

Market Significance & Competitive Positioning

Commercial Implications

• Pricing Strategy: Premium pricing expected given breakthrough designation and high unmet need in rare sarcoma
• Market Access: Priority review status likely facilitates rapid inclusion in provincial reimbursement lists
• Physician Adoption: Established safety profile from previous indications supports rapid uptake in sarcoma specialty centers
• Revenue Impact: While ASPS is rare, the approval validates the combination’s broad applicability across tumor types

Development Strategy & Future Outlook

• Additional Indications: Ongoing trials exploring the combination in other rare tumors and solid malignancies
• Biomarker Development: Research into predictive biomarkers to optimize patient selection across indications
• International Expansion: Potential partnerships for global development leveraging strong clinical data package
• Pipeline Validation: Success reinforces Sino Biopharmaceutical’s strategy of developing proprietary combinations rather than single-agent approaches

Industry Context & Regulatory Environment

• China Oncology Innovation: Part of broader trend of Chinese pharmaceutical companies developing novel combinations for domestic and global markets
• Rare Disease Incentives: Benefits from China’s evolving regulatory framework that encourages development of therapies for rare conditions
• Competitive Landscape: Limited competition in ASPS space creates opportunity for market leadership despite small patient population
• Reimbursement Support: Breakthrough therapy designation typically associated with favorable reimbursement decisions in China

Forward‑Looking Statements
This brief contains forward-looking statements regarding commercial performance, market penetration, and development plans. Actual results may differ due to risks including market adoption rates, competitive dynamics, reimbursement decisions, and regulatory developments.-Fineline Info & Tech